NOX-E36 (emapticap pegol) has completed Phase 1 and Phase 2 clinical studies, establishing its ability to target macrophages in a dose-dependent manner and its safety and tolerability profile in over 100 subjects. Building on these data, we are now focused on its application in oncology where preclinical data has shown activity in models of solid tumors like pancreas and liver cancer. TME Pharma plans to put NOX-E36 back into the clinic in 2022 as part of its clinical development plan to treat solid tumors.
Mechanism of Action
NOX-E36 is an injectable PEGylated L-stereoisomer RNA aptamer conjugated to 40kD PEG that directly binds and neutralizes the human chemokine CCL2 (C-C motif Ligand 2, also called Monocyte Chemoattractant Protein-1) as well as three highly related chemokines. Chemokines can be thought of as road signs in the body that can direct movement of cells that encounter them. Like road signs, chemokines are anchored in place (location information) and contain directions, such as “enter here”, for cells that can “see” them with the appropriate receptors. CCL2 is one of the chemokines that regulate migration and infiltration of key components of the innate immune system called monocytes/macrophages. Both CCL2 and its receptor CCR2 are implicated in cancer spread and immune privilege of tumors. One key function of CCL2 is the recruitment of immunosuppressive cell populations of the innate immune system such as Tumor Associated Macrophages (TAMs). Removing TAMs from the tumor microenvironment with NOX-E36 should allow an improved immune response against tumors.
Recent NOX-E36 press releases
Clinical trials with NOX-E36